HORIZONS



Understanding the impact of cancer diagnosis and treatment on everyday life

## 36 MONTH ENDOMETRIAL CANCER CRF

## FOR STAFF USE ONLY

## **CRF Completion Instructions**

- Please complete as much of the CRF as possible
- Please refer to your copies of previous CRFs when completing this 36 month CRF: please complete any additional treatment details that were not captured at 24 months (for example, additional treatments, or end dates of those ongoing in earlier CRFs)
- If you have any queries, please contact the HORIZONS
   Co-ordinating Centre, email address <u>HORIZONS@soton.ac.uk</u>
- Please tick boxes when appropriate
- When you have completed the CRF, please keep a copy for your own records and return a copy to us, by post, fax or email along with the completed return cover sheet

Participant's Study ID		/[		/							
Participant's date of bir	th	d	C	m	n	n	У	У	У	У	

Has the participant developed any NEW co-morbidities (which were not recorded in any previous CRFs)? (please tick all that apply in the tables below and overleaf)

Myocardial infarct	
Angina/coronary artery disease	
Congestive Heart Failure	
Cardiac Arrhythmias	
Hypertension	
Venous Disease (PE/DVT)	
Peripheral Arterial Disease	
Restrictive Lung Disease or COPD (chronic bronchitis, emphysema, asthma etc.)	
Liver Disease (portal hypertension, chronic/acute hepatitis, cirrhosis etc.)	
Stomach Ulcers or Inflammatory Bowel Disease	
Acute or Chronic Pancreatitis	
End-stage Renal Disease (chronic renal insufficiency, dialysis etc.)	
Thyroid problems (hyperthyroidism, hypothyroidism etc.)	
Diabetes Mellitus Type 1	
Diabetes Mellitus Type 2	
Stroke/TIA	
Dementia	
Paralysis (paraplegia or hemiplegia)	
Neuromuscular Condition (multiple sclerosis, Parkinson's, myasthenia gravis, other	
chronic neuromuscular disorder)	
Clinical diagnosis of anxiety	

Clir	nical diagnosis of depression	
Psy	rchiatric Diagnosis (e.g. schizophrenia, bipolar disorder)	
Ost	teoarthritis	
Rhe	eumatoid Arthritis	
	ner Rheumatological Disease (systemic lupus, mixed connective tissue disorder, polyositis, rheumatic polymyositis, scleroderma etc.)	
НΙ\	//AIDS	
	ohol Abuse (or history of, must be accompanied by social, behavioural or medical comations)	
	ug/Substance Abuse (or history of, must be accompanied by social, behavioural or dical complications)	
Mo	orbid Obesity	
Oth	ner (please give details)	
Oth	ner (please give details)	
Oth	ner (please give details)	
s the	e participant pre or post menopause? (please tick one box)	
	Pre menopause	
	Post menopause	
	Unknown	

Participant's Study ID / / /

Participant's Study ID	<b>/</b> $\Box$	/		

What treatments has the participant received **since those captured in any previous CRFs**, please tick ALL that apply and write details in the spaces provided. Please add end dates for any treatments which were ongoing previously (table continued overleaf).

Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treatment was not completed as planned, please give a reason why
Surgery	Please give details below of surgery (e.g. surgery for cancer, palliative surgery)		//20		
Combined Chemo- radiotherapy	Combined chemo-radiotherapy  Please also tick the boxes below/ overleaf to indicate which treat- ments were combined. If the combined treatments are not mentioned below/overleaf, please give details on line		// 20	//20	
Chemotherapy	Carboplatin		// 20	// 20	
	Carboplatin with paclitaxel		//20	//20	
	CAP: cyclophosphamide, doxorubicin and cisplatin/carboplatin		// 20	// 20	
	Other chemotherapy (please describe)		// 20	// 20	
	Chemotherapy number of cycles	(please er	nter on line)		
Radiotherapy	External radiotherapy		//20	// 20	
	Combined external radiotherapy and brachytherapy (please also complete brachytherapy details overleaf)		//20	//20	
	Number of radiotherapy fractions (please enter on line)				
	Dose for each radiotherapy fraction (please enter on line)				

Participant's Study ID / /					
Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of oth- er treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treat- ment was not completed as planned, please give a reason why
Radiotherapy (cont.)	Brachytherapy LOW dose rate		//20	//20	
	Brachytherapy HIGH dose rate		//20	//20	
	Brachytherapy PULSED dose rate		//20	//20	
Additional Treatment	If any additional treatment has been given please describe		//20	// 20	
loro any of t	ha traatmonts datailas	l above a	rivan with <b>nalli</b> e	ativo intont?	

Were any of the treat	ments detaile	d above given witl	h palliative intent?
(please tick one box)	Yes	No	Unknown
If yes, please indicate v	which treatme	ents?	

Participant's Study ID / / /
Has the participant had a <b>local</b> recurrence of their endometrial cancer? (please tick one box)  Yes  No  Unknown
If the participant has had a local recurrence, on what date was the recurrence
diagnosed?  d d m m y y y y
Since the participant's diagnosis of endometrial cancer, has there been any evidence of distant metastatic disease? (please tick one box)
Yes No Unknown
If you have answered "yes" to the above question, on what date was the metastatic disease diagnosed:
Please provide details of the site(s) of distant metastatic disease:
s the participant taking part in a clinical trial? (please tick one box)  Yes  No  Unknown
If you answered "yes" to the above question, please give the NAME of the clinical trial the participant is taking part in  Name of clinical trial

Participant's Study ID /			
Since the participant's diagnosis of endome with another new primary cancer? (please			
Yes No	Unknown		
If you answered "yes" to the above question about the participant's new cancer diagno			
Type of cancer			
Date of diagnosis	//20		
Treatment received			
Date treatment ended (if finished)	//20		
What type of follow-up care is the particip			
Routine/regular hospital clinic based follo face-to-face or by telephone)	ow-up (medical or nurse led,		
Primary care based follow-up			
Patient initiated follow-up (also known as (PTFU), open access follow-up, or suppor			
If the participant is receiving patient-initiated follow-up, on what date were they discharged to this?			

Participant	's Study ID / /
•	cipant been referred to any of the following services and/or had a is Assessment? (please tick all that apply)
Participant h	as been referred to palliative care services
If available, plea	ase give reason for referral (e.g. end of life care, symptom management)
Participant h	as been referred to psychological services
If ticked, please	provide route to referral (e.g. GP, Improving Access to Psychological Therapies)
Participant h	as been referred to community services
-	provide more details below:
Participant h	as had an HNA (holistic needs assessment)
Participant h	as been referred to fertility services
Participant's	date of death d d / m m / y y y y
Cause of par	ticipant's death
1) a)	
1) b)	
1) c)	
2)	
Cause of dea	th not known
Please add	your name and signature and the date that you completed this CRF
Name	Signature
Date CRF co	ompleted dd/mm//yyyy